GB Patent

GB2103927A — Sub-dermal sustained-release pharmaceutical implants

Assigned to Council of Scientific and Industrial Research CSIR · Expires 1983-03-02 · 43y expired

What this patent protects

Sub-dermal sustained-release pharmaceutical implants for the administration release of a drug over an extended period in a human or animal system are prepared by microencapsulating a predetermined portion of the drug into micro- capsules of non-toxic bio-degradeable material (e.g…

USPTO Abstract

Sub-dermal sustained-release pharmaceutical implants for the administration release of a drug over an extended period in a human or animal system are prepared by microencapsulating a predetermined portion of the drug into micro- capsules of non-toxic bio-degradeable material (e.g. ethyl cellulose, cellulose acetate phthalate), dispersing said microcapsules into a supporting matrix formed from a blend of the remaining portion of the drug with a biocompatible/bioabsorbable biodegradable material (e.g. cholesterol, sitosterol), and compressing the mixture so obtained into pellets for use as sub-dermal implants. The drug may be acedapsone or primaquine phosphate.

Drugs covered by this patent

Patent Metadata

Patent number
GB2103927A
Jurisdiction
GB
Classification
—
Expires
1983-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Council of Scientific and Industrial Research CSIR
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.